Stocks › NBIX

NEUROCRINE BIOSCIENCES INC

NBIX·Nasdaq·United States United States·USD
$150.57
-6.02 (-3.84%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
NBIX
NEUROCRINE BIOSCIENCES INC · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
NBIXS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of NBIX by members of U.S. Congress · 28 on record
All congressional trades →
PoliticianStockTypeFiledTraded
Lisa C. McClainLisa C. McClainHouse · R · MI NBIXNEUROCRINE BIOSCIENCES INC · Stock Sale
$1,001 - $15,000
Aug 13, 2025 Jun 17, 2025 Filing ↗
Lisa C. McClainLisa C. McClainHouse · R · MI NBIXNEUROCRINE BIOSCIENCES INC · Stock Purchase
$1,001 - $15,000
Aug 13, 2025 Jun 11, 2025 Filing ↗
Ro KhannaRo KhannaHouse · D · CA NBIXNEUROCRINE BIOSCIENCES INC · Common Stock Purchase
$1,001 - $15,000
Mar 3, 2023 Feb 10, 2023 Filing ↗
Ro KhannaRo KhannaHouse · D · CA NBIXNEUROCRINE BIOSCIENCES INC · Common Stock Purchase
$1,001 - $15,000
Jan 6, 2023 Dec 6, 2022 Filing ↗
Michael T. McCaulMichael T. McCaulHouse · R · TX NBIXNEUROCRINE BIOSCIENCES INC · Stock Sale
$1,001 - $15,000
Jan 27, 2022 Dec 14, 2021 Filing ↗
Michael T. McCaulMichael T. McCaulHouse · R · TX NBIXNEUROCRINE BIOSCIENCES INC · Stock Purchase
$1,001 - $15,000
Jul 16, 2021 Jun 24, 2021 Filing ↗
Michael T. McCaulMichael T. McCaulHouse · R · TX NBIXNEUROCRINE BIOSCIENCES INC · Stock Purchase
$15,001 - $50,000
Jul 16, 2021 Jun 24, 2021 Filing ↗
Michael T. McCaulMichael T. McCaulHouse · R · TX NBIXNEUROCRINE BIOSCIENCES INC · Stock Purchase
$15,001 - $50,000
Apr 19, 2021 Mar 9, 2021 Filing ↗
Michael T. McCaulMichael T. McCaulHouse · R · TX NBIXNEUROCRINE BIOSCIENCES INC · Stock Purchase
$15,001 - $50,000
Apr 19, 2021 Mar 9, 2021 Filing ↗
Gilbert Ray Cisneros, Jr.Gilbert Ray Cisneros, Jr.House · D · CA NBIXNEUROCRINE BIOSCIENCES INC · Stock Purchase
$1,001 - $15,000
Jan 11, 2021 Dec 21, 2020 Filing ↗
Michael T. McCaulMichael T. McCaulHouse · R · TX NBIXNEUROCRINE BIOSCIENCES INC · Stock Purchase
$50,001 - $100,000
Jan 7, 2021 Nov 12, 2020 Filing ↗
Michael T. McCaulMichael T. McCaulHouse · R · TX NBIXNEUROCRINE BIOSCIENCES INC · Stock Purchase
$50,001 - $100,000
Jan 7, 2021 Nov 12, 2020 Filing ↗
Michael T. McCaulMichael T. McCaulHouse · R · TX NBIXNEUROCRINE BIOSCIENCES INC · Stock Sale
$50,001 - $100,000
Nov 30, 2020 Oct 1, 2020 Filing ↗
Michael T. McCaulMichael T. McCaulHouse · R · TX NBIXNEUROCRINE BIOSCIENCES INC · Stock Sale
$50,001 - $100,000
Nov 30, 2020 Oct 1, 2020 Filing ↗
Gilbert Ray Cisneros, Jr.Gilbert Ray Cisneros, Jr.House · D · CA NBIXNEUROCRINE BIOSCIENCES INC · Stock Sale
$1,001 - $15,000
Aug 19, 2020 Jul 21, 2020 Filing ↗
Michael T. McCaulMichael T. McCaulHouse · R · TX NBIXNEUROCRINE BIOSCIENCES INC · Stock Purchase
$1,001 - $15,000
May 6, 2020 Mar 2, 2020 Filing ↗
Michael T. McCaulMichael T. McCaulHouse · R · TX NBIXNEUROCRINE BIOSCIENCES INC · Stock Sale
$1,001 - $15,000
May 6, 2020 Mar 2, 2020 Filing ↗
Michael T. McCaulMichael T. McCaulHouse · R · TX NBIXNEUROCRINE BIOSCIENCES INC · Stock Sale
$1,001 - $15,000
Jan 29, 2020 Dec 12, 2019 Filing ↗
Michael T. McCaulMichael T. McCaulHouse · R · TX NBIXNEUROCRINE BIOSCIENCES INC · Stock Sale
$1,001 - $15,000
Jan 29, 2020 Dec 12, 2019 Filing ↗
Michael T. McCaulMichael T. McCaulHouse · R · TX NBIXNEUROCRINE BIOSCIENCES INC · Stock Purchase
$15,001 - $50,000
Feb 25, 2019 Jan 17, 2019 Filing ↗
Michael T. McCaulMichael T. McCaulHouse · R · TX NBIXNEUROCRINE BIOSCIENCES INC · Stock Purchase
$15,001 - $50,000
Feb 25, 2019 Jan 18, 2019 Filing ↗
Michael T. McCaulMichael T. McCaulHouse · R · TX NBIXNEUROCRINE BIOSCIENCES INC · Stock Purchase
$15,001 - $50,000
Feb 25, 2019 Jan 16, 2019 Filing ↗
Michael T. McCaulMichael T. McCaulHouse · R · TX NBIXNEUROCRINE BIOSCIENCES INC · Stock Purchase
$15,001 - $50,000
Feb 25, 2019 Jan 17, 2019 Filing ↗
Michael T. McCaulMichael T. McCaulHouse · R · TX NBIXNEUROCRINE BIOSCIENCES INC · Stock Purchase
$15,001 - $50,000
Feb 25, 2019 Jan 15, 2019 Filing ↗
Michael T. McCaulMichael T. McCaulHouse · R · TX NBIXNEUROCRINE BIOSCIENCES INC · Stock Purchase
$15,001 - $50,000
Feb 25, 2019 Jan 18, 2019 Filing ↗

Whale Activity

Position changes in NBIX reported for 2026-09-30 by 871 institutional filers
Increased: 301New: 100Held: 88Decreased: 255Closed: 97No prior filing: 30
  • Increased301
  • New100
  • Held88
  • Decreased255
  • Closed97
  • No prior filing30
FilerSharesValueChange
BlackRock, Inc.14.9M$2.11Bincreased
DODGE & COX5.5M$780.8Mdecreased
JPMORGAN CHASE & CO5.3M$733.0Mdecreased
VANGUARD PORTFOLIO MANAGEMENT LLC5.1M$717.7Mincreased
STATE STREET CORP4.8M$682.0Mincreased
VANGUARD CAPITAL MANAGEMENT LLC4.6M$649.7Mincreased
AQR CAPITAL MANAGEMENT LLC3.1M$422.5Mdecreased
Vestal Point Capital, LP2.5M$354.6Mincreased
RENAISSANCE TECHNOLOGIES LLC2.3M$326.3Mdecreased
GEODE CAPITAL MANAGEMENT, LLC2.1M$301.0Mdecreased
BNP Paribas Asset Management Holding S.A.1.5M$215.9M—
MORGAN STANLEY1.4M$204.8Mincreased

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by NBIX insiders, by quarter · Form 4
-500.0K-250.0K0250.0K500.0K2025 Q1: -272.1K2025 Q12025 Q2: -39.6K2025 Q22025 Q3: -187.0K2025 Q32025 Q4: -64.8K2025 Q42026 Q1: -36.4K2026 Q12026 Q2: -365.2K2026 Q22026 Q3: -35.5K2026 Q32026 Q4: -30.0K2026 Q4

Recent Insider Transactions

1,754 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
LYONS GARY ADirector · Director Sale −5,689 $165.15 $940K Nov 17, 2026 Form 4 ↗
LYONS GARY ADirector · Director Sale −4,100 $165.90 $680K Nov 17, 2026 Form 4 ↗
LYONS GARY ADirector · Director Sale −4,011 $163.94 $658K Nov 17, 2026 Form 4 ↗
LYONS GARY ADirector · Director Sale −1,200 $163.11 $196K Nov 17, 2026 Form 4 ↗
MORROW GEORGE JDirector · Director Sale −908 $165.71 $150K Nov 3, 2026 Form 4 ↗
MORROW GEORGE JDirector · Director Sale −600 $163.71 $98K Nov 3, 2026 Form 4 ↗
MORROW GEORGE JDirector · Director Sale −1,500 $167.72 $252K Nov 3, 2026 Form 4 ↗
MORROW GEORGE JDirector · Director Sale −1,466 $166.77 $244K Nov 3, 2026 Form 4 ↗
MORROW GEORGE JDirector · Director Sale −1,300 $168.53 $219K Nov 3, 2026 Form 4 ↗
MORROW GEORGE JDirector · Director Sale −1,226 $164.74 $202K Nov 3, 2026 Form 4 ↗
MORROW GEORGE JDirector · Director Sale −100 $162.05 $16K Nov 3, 2026 Form 4 ↗
MORROW GEORGE JDirector · Director Sale −100 $158.18 $16K Nov 3, 2026 Form 4 ↗
MORROW GEORGE JDirector · Director Sale −4,300 $145.86 $627K Nov 2, 2026 Form 4 ↗
MORROW GEORGE JDirector · Director Sale −1,900 $144.98 $275K Nov 2, 2026 Form 4 ↗
MORROW GEORGE JDirector · Director Sale −1,300 $146.76 $191K Nov 2, 2026 Form 4 ↗
MORROW GEORGE JDirector · Director Sale −300 $149.00 $45K Oct 30, 2026 Form 4 ↗
Boyer David W.Chief Corp. Affairs Officer Sale −826 $157.45 $130K Sep 14, 2026 Form 4 ↗
ABERNETHY MATTChief Financial Officer Sale −2,311 $157.20 $363K Sep 14, 2026 Form 4 ↗
Delaet IngridChief Regulatory Officer Tax withholding −2,419 $156.22 $378K Sep 11, 2026 Form 4 ↗
Delaet IngridChief Regulatory Officer Grant / award +4,483 $0.00 $0 Sep 11, 2026 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding NBIX · SEC Form N-PORT
FundSharesValue% of fundAs of
Dodge & Cox Stock Fund
Dodge & Cox Funds
4.0M$668.1M0.56%Jun 30, 2026
iShares Core S&P Mid-Cap ETF
iShares Trust
3.4M$579.9M0.47%Jun 30, 2026
VANGUARD TOTAL STOCK MARKET INDEX FUND
VANGUARD INDEX FUNDS
3.2M$538.2M0.02%Jun 30, 2026
VANGUARD SMALL-CAP INDEX FUND
VANGUARD INDEX FUNDS
2.3M$388.5M0.21%Jun 30, 2026
JPMorgan Growth Advantage Fund
J.P. Morgan Mutual Fund Investment Trust
1.4M$229.0M1.02%Jun 30, 2026
VANGUARD SMALL-CAP GROWTH INDEX FUND
VANGUARD INDEX FUNDS
1.3M$224.1M0.48%Jun 30, 2026
VANGUARD EXTENDED MARKET INDEX FUND
VANGUARD INDEX FUNDS
1.2M$194.3M0.20%Jun 30, 2026
JPMorgan Mid Cap Growth Fund
JPMorgan Trust II
1.1M$188.2M1.42%Jun 30, 2026
State Street SPDR S&P MidCap 400SM ETF Trust
SPDR S&P MIDCAP 400 ETF TRUST
773.6K$130.4M0.46%Jun 30, 2026
iShares Biotechnology ETF
iShares Trust
700.1K$118.0M1.30%Jun 30, 2026

Mutual funds and ETFs whose N-PORT filings list NBIX's shares (CUSIP 64125C109), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • Vanguard Portfolio ManagementSCHEDULE 13G · passive (13G) · 5.1M shares5.0%
    Oct 30, 2026 · ↗
  • JPMORGAN CHASE & CO.SCHEDULE 13G/A · passive (13G) · 5.3M shares5.2%
    Oct 15, 2026 · ↗
  • JPMORGAN CHASE & CO.SCHEDULE 13G/A · passive (13G) · 6.3M shares6.3%
    Jul 27, 2026 · ↗
  • Vanguard Capital ManagementSCHEDULE 13G · passive (13G) · 5.3M shares5.2%
    Apr 30, 2026 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming neurocrine biosciences as client
$0$1.3M$2.5M$3.8M$5.0M2023 Q1: $1.0M2023 Q2: $1.0M2023 Q3: $1.0M2023 Q4: $1.0M20232024 Q1: $1.1M2024 Q2: $1.1M2024 Q3: $1.1M2024 Q4: $1.1M20242025 Q1: $1.1M2025 Q2: $1.1M2025 Q3: $1.1M2025 Q4: $1.2M20252026 Q1: $1.1M2026 Q2: $1.2M2026 Q3: $1.2M2026
  • TARPLIN, DOWNS & YOUNG, LLCNEUROCRINE BIOSCIENCES, INC. · 2026 Q3 · HCR, MMM, BUD$110K
    Filing ↗
  • BGR GOVERNMENT AFFAIRSNEUROCRINE BIOSCIENCES, INC. · 2026 Q3 · PHA$60K
    Filing ↗
  • NEUROCRINE BIOSCIENCES, INCNEUROCRINE BIOSCIENCES, INC · 2026 Q3 · MMM, HCR, BUD, TAX$940K
    Filing ↗
  • CAPITOL COUNSEL LLCNEUROCRINE BIOSCIENCES, INC. · 2026 Q3 · BUD, HCR, MMM$60K
    Filing ↗
  • BGR GOVERNMENT AFFAIRSNEUROCRINE BIOSCIENCES, INC. · 2026 Q2 · PHA$60K
    Filing ↗

Government Contracts

Federal awards to NEUROCRINE BIOSCIENCES INC · USAspending

No federal contract awards found for NEUROCRINE BIOSCIENCES INC.

U.S. Patents

Recent USPTO applications naming NEUROCRINE BIOSCIENCES INC

No USPTO patent applications found for NEUROCRINE BIOSCIENCES INC.

Annual Financials

From NBIX's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023FY2022FY2021
Revenue$2.86B$2.36B$1.89B$1.49B$1.13B
Operating income$619.1M$570.5M$250.9M$249.0M$102.5M
Net income$478.6M$341.3M$249.7M$154.5M$89.6M
Diluted EPS$4.67$3.29$2.47$1.56$0.92
Operating cash flow$782.7M$595.4M$389.9M$339.4M$256.5M
Cash and equivalents$713.0M$233.0M$251.1M$262.9M$340.8M
Total assets$4.63B$3.72B$3.25B$2.37B$2.07B
Total liabilities$1.38B$1.13B$1.02B$660.9M$698.5M
Shareholders' equity$3.25B$2.59B$2.23B$1.71B$1.37B

As NEUROCRINE BIOSCIENCES INC tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 11, 2026 ↗

Stock Splits

Every split and reverse split in the price history

No stock splits in NBIX's price history.

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 2.02, 9.01Results of operationsNov 2, 2026
    EDGAR ↗
  • 8-K · Items 5.02Officer / director changeSep 28, 2026
    EDGAR ↗
  • 8-K/A · Items 9.01Jul 31, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsJul 30, 2026
    EDGAR ↗
  • 8-K · Items 5.02, 5.07Officer / director change · Shareholder voteMay 28, 2026
    EDGAR ↗
  • 8-K · Items 1.01, 2.01, 2.03, 7.01, 9.01Material agreement · Acquisition or disposition · Direct financial obligationMay 18, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsMay 5, 2026
    EDGAR ↗

About NEUROCRINE BIOSCIENCES INC

From SEC EDGAR company records
Industry (SIC 2836)Biological Products, (No Diagnostic Substances)
SectorHealthcare
HeadquartersSAN DIEGO, CA
IncorporatedDE